Mr. Liam Woods:

Some of the drugs we are speaking of and that Mr. Flanagan referred to, we would acknowledge, are expensive. The processes we engage in can reduce the cost and allow us to provide more care to a wider number of people. The motivations of the companies is not a matter for us to comment on. We certainly experience the high cost of new drugs and new technologies. As the Deputy rightly said, I am sure the companies themselves would reflect back on the research, other requirements and, indeed, the products that never come to market. However, it is not for us to comment on their motivations. We experience high cost, but also, in some cases, high benefit, it has to be said.